Intraperitoneal Immunotherapy and Bone Drug for Stomach Cancer Belly Fluid
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer called gastric adenocarcinoma that has spread to the lining of your belly, causing fluid buildup (malignant ascites).
- You are between 18 and 75 years old.
- You have not had immunotherapy or any drugs injected into your belly in the last 4 weeks.
- You are generally well enough to carry out most daily activities and your doctor expects you to live more than 3 months.
- Your blood counts, liver, and kidney function are within safe ranges (specific lab results needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
This study tests a new combination of drugs and focused radiation to treat belly fluid caused by digestive system cancers. It aims to shrink tumors and reduce fluid buildup, potentially improving symptoms and quality of life.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This study tests a combination of two treatments for stomach cancer that has spread to the lining of the belly. It uses an immunotherapy drug (tislelizumab) plus standard chemotherapy (SOX) and a heated chemotherapy treatment directly into the belly (HIPEC) to see if this approach is safe and effective.
This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
Hear when a new Cancer of Stomach, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.